We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+14.54%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.47B
AUM Growth
-$118M
Cap. Flow
-$497M
Cap. Flow %
-20.15%
Top 10 Hldgs %
35.06%
Holding
147
New
13
Increased
26
Reduced
28
Closed
38

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$70.1M
2
ADPT
Adeptus Health Inc
ADPT
+$48.6M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$22.8M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$17.2M
5
XNPT
XENOPORT, INC.
XNPT
+$15.9M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$41.3M
2
NXTM
NxStage Medical Inc.
NXTM
+$32.2M
3
ELGX
Endologix Inc
ELGX
+$28.8M
4
GSK icon
GSK
GSK
+$24.8M
5
LOXO
Loxo Oncology, Inc
LOXO
+$22.5M

Sector Composition

Rank Sector Weight
1 Healthcare 68.33%
2 Financials 4.33%
3 Technology 0.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMPR
51
DELISTED
IMPRIVATA, INC COM
IMPR
$13.6M 0.55%
1,206,418
+55,278
+5% +$651K
NSTG
52
DELISTED
NanoString Technologies, Inc.
NSTG
$13M 0.53%
880,622
– –
LKFT
53
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$11.5M 0.47%
183,000
-258,085
-59% -$13.2M
XLRN
54
DELISTED
Acceleron Pharma
XLRN
$10.4M 0.42%
+213,491
New +$7.68M
TRUP icon
55
Trupanion
TRUP
$1.16B
$10.4M 0.42%
1,062,214
-516,711
-33% -$4.08M
TNXP icon
56
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– –
IVTY
57
DELISTED
Invuity, Inc
IVTY
$9.51M 0.39%
1,078,218
+877,150
+436% +$10.4M
EPIX
58
DELISTED
ESSA Pharma
EPIX
$8.5M 0.34%
92,964
– –
HTWR
59
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$8.06M 0.33%
159,961
+25,761
+19% +$1.21M
FOMX
60
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$7.7M 0.31%
948,934
– –
RIGL icon
61
Rigel Pharmaceuticals
RIGL
$750M
$7.27M 0.29%
239,786
– –
LOXO
62
DELISTED
Loxo Oncology, Inc
LOXO
$7.14M 0.29%
251,000
-837,225
-77% -$22.5M
ARCT icon
63
Arcturus Therapeutics
ARCT
$172M
$6.72M 0.27%
152,845
+10,367
+7% +$467K
NEOS
64
DELISTED
Neos Therapeutics, Inc
NEOS
$6.56M 0.27%
458,332
– –
ARAV
65
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.08M 0.25%
81,751
+35,584
+77% +$2.39M
OXFD
66
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$5.98M 0.24%
519,670
– –
EYPT icon
67
EyePoint Inc
EYPT
$1.12B
$5.89M 0.24%
122,211
+25,000
+26% +$974K
CASM
68
DELISTED
CAS Medical Systems, Inc.
CASM
$5.66M 0.23%
3,200,000
– –
MYOK
69
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.5M 0.22%
+375,000
New +$4.59M
LRMR icon
70
Larimar Therapeutics
LRMR
$384M
$5.31M 0.22%
70,305
+24,182
+52% +$3.88M
EGLT
71
DELISTED
Egalet Corporation
EGLT
$5.26M 0.21%
477,123
– –
VYGR icon
72
Voyager Therapeutics
VYGR
$192M
$5.15M 0.21%
+235,294
New +$5.42M
ATXS
73
DELISTED
Astria Therapeutics
ATXS
$5.1M 0.21%
10,726
+251
+2% +$120K
ATRS
74
DELISTED
Antares Pharma, Inc.
ATRS
$4.82M 0.2%
3,983,440
-11,467,684
-74% -$16M
ALDX icon
75
Aldeyra Therapeutics
ALDX
$102M
$4.68M 0.19%
690,538
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2015 Portfolio in Review

As of Q4 2015, Deerfield Management held 147 positions worth $2.47B, down 4.6% from $2.59B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management withdrew a net $497M in Q4 2015, closing 38 positions and reducing 28 holdings. Its most notable exit was bluebird bio, an estimated $41.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 69% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Five Prime Therapeutics, Inc. worth $28.2M.

  • Deerfield Management's largest Q4 2015 buy was Five Prime Therapeutics, Inc.: 680,000 shares worth $28.2M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015, an estimated $70.1M increase.
  • Deerfield Management's biggest Q4 2015 reduction was NxStage Medical Inc., cutting an estimated $32.2M.
  • Deerfield Management fully exited bluebird bio in Q4 2015, selling an estimated $41.3M.
  • Deerfield Management's ten largest holdings make up 35% of its $2.47B portfolio in Q4 2015.
  • Deerfield Management opened 13 new positions and closed 38 in Q4 2015.
  • Deerfield Management's portfolio value fell 4.6% quarter-over-quarter to $2.47B.

Based on Deerfield Management's 13F filing for Q4 2015, filed 16 Feb 2016.